Mestag Therapeutics Competitors and Similar CompaniesClear all
Mestag Therapeutics's competitors and similar companies include MaxCyte, Fusion Pharmaceuticals, TScan Therapeutics and Immunicom.
 Mestag Therapeutics Mestag Therapeutics (formerly Biotech 3) is an immunotherapy company developing therapies for patients with oncology and inflammatory diseases. |  MaxCyte MaxCyte (formerly known as Theramed) is a cell engineering company focused on providing platform technologies for cell-based research as well as cell therapeutic discovery, development, and commercialization. |  Fusion Pharmaceuticals Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer. |  TScan Therapeutics TScan Therapeutics is a biotechnology company that develops cancer-targeting therapies. |  Immunicom Immunicom is a company that develops and commercializes a non-drug-based cancer therapy in order to reduce treatment side effects and enhance its response rates. | |
Founding Date | Founding Date 2020 | Founding Date 1998 | Founding Date 2014 | Founding Date 2018 | Founding Date 2013 |
Type | Type Private | Type Public | Type Subsidiary | Type Public | Type Private |
Tags | |||||
Locations | Locations HQ | Locations Gaithersburg, US HQ Alderley Edge, GB | Locations Hamilton, CA HQ Boston, US | Locations Waltham, US HQ | Locations San Diego, US HQ |
Employees | Employees 552% increase | Employees 65 | Employees 101 | Employees 7316% increase | Employees 22 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 387.9 m | Valuation ($) N/A | Valuation ($) 251.6 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $33m (FY, 2025) | Revenue (est.) $2.1m (FY, 2023) | Revenue (est.) $10.3m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $6.2m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $26.8m (FY, 2025) | Gross profit $2.1m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ($44.6m) (FY, 2025) | Net income ($94.9m) (FY, 2023) | Net income ($129.8m) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 31.3m | Total funding raised $ 170.9m | Total funding raised $ 137.5m | Total funding raised $ 21.9m |
For sources of this data, please see the company profile
View Company Profiles
MaxCyte
HQ
Gaithersburg, US
Employees
65
MaxCyte (formerly known as Theramed) is a cell engineering company focused on providing platform technologies for cell-based research as well as cell therapeutic discovery, development, and commercialization.
View companyFusion Pharmaceuticals
HQ
Hamilton, CA
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer.
View companyTScan Therapeutics
HQ
Waltham, US
Employees
73↑ 16% increase
TScan Therapeutics is a biotechnology company that develops cancer-targeting therapies.
View companyImmunicom
HQ
San Diego, US
Employees
22
Immunicom is a company that develops and commercializes a non-drug-based cancer therapy in order to reduce treatment side effects and enhance its response rates.
View company